M.N. Schwartz, BS, M.A. Ferrada, MD, K.B. Gribbons, BS, J.S. Rosenblum, BS, W. Goodspeed, RN, E. Novakovich, RN, P.C. Grayson, MD, MSc, Systemic Autoimmunity Branch, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, Maryland.
C.A. Rimland, PhD, Systemic Autoimmunity Branch, NIH, NIAMS, Bethesda, Maryland, and University of North Carolina at Chapel Hill School of Medicine, Medical Scientist Training Program, Chapel Hill, North Carolina.
J Rheumatol. 2020 Dec 1;47(12):1785-1792. doi: 10.3899/jrheum.190828. Epub 2020 Apr 1.
To assess the validity and clinical utility of the Brief Illness Perception Questionnaire (BIPQ) to measure illness perceptions in multiple forms of vasculitis.
Patients with giant cell arteritis (GCA), Takayasu arteritis (TA), antineutrophil cytoplasmic antibody-associated vasculitis (AAV), and relapsing polychondritis (RP) were recruited into a prospective, observational cohort. Patients independently completed the BIPQ, Multidimensional Fatigue Inventory (MFI), Medical Outcomes Study 36-item Short Form survey (SF-36), and a patient global assessment (PtGA) at successive study visits. Physicians concurrently completed a physician global assessment (PGA) form. Illness perceptions, as assessed by the BIPQ, were compared to responses from the full-length Revised Illness Perception Questionnaire (IPQ-R) and to other clinical outcome measures.
There were 196 patients (GCA = 47, TA = 47, RP = 56, AAV = 46) evaluated over 454 visits. Illness perception scores in each domain were comparable between the BIPQ and IPQ-R (3.28 vs 3.47, = 0.22). Illness perceptions differed by type of vasculitis, with the highest perceived psychological burden of disease in RP. The BIPQ was significantly associated with all other patient-reported outcome measures (rho = |0.50-0.70|, < 0.0001), but did not correlate with PGA (rho = 0.13, = 0.13). A change in the BIPQ composite score of ≥ 7 over successive visits was associated with concomitant change in the PtGA. Change in the MFI and BIPQ scores significantly correlated over time (rho = 0.38, = 0.0008).
The BIPQ is an accurate and valid assessment tool to measure and monitor illness perceptions in patients with vasculitis. Use of the BIPQ as an outcome measure in clinical trials may provide complementary information to physician-based assessments.
评估Brief Illness Perception Questionnaire（BIPQ）在多种血管炎形式中测量疾病认知的有效性和临床实用性。
招募巨细胞动脉炎（GCA）、Takayasu 动脉炎（TA）、抗中性粒细胞胞质抗体相关性血管炎（AAV）和复发性多软骨炎（RP）患者进入前瞻性观察队列。患者在连续的研究就诊时独立完成 BIPQ、多维疲劳量表（MFI）、医疗结局研究 36 项简短形式调查（SF-36）和患者总体评估（PtGA）。医生同时完成医生总体评估（PGA）表格。使用 BIPQ 评估的疾病认知与完整的修订疾病认知问卷（IPQ-R）的反应以及其他临床结果测量进行比较。
在 454 次就诊中评估了 196 例患者（GCA = 47，TA = 47，RP = 56，AAV = 46）。BIPQ 各领域的疾病认知评分与 IPQ-R 相当（3.28 与 3.47， = 0.22）。疾病认知因血管炎类型而异，RP 患者的疾病心理负担最高。BIPQ 与所有其他患者报告的结果测量显著相关（rho = |0.50-0.70|， < 0.0001），但与 PGA 不相关（rho = 0.13， = 0.13）。连续就诊中 BIPQ 综合评分的变化≥7 与同期 PtGA 的变化相关。MFI 和 BIPQ 评分的变化随时间显著相关（rho = 0.38， = 0.0008）。
BIPQ 是一种准确有效的评估工具，可用于测量和监测血管炎患者的疾病认知。在临床试验中使用 BIPQ 作为结果测量可能会为基于医生的评估提供补充信息。
